Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Anderson (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), H. Hoch (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America). Nighttime short-acting beta-agonist (SABA) in asthma and COPD. 859

Member's Comments

No comment yet.

Related content which might interest you: Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Formoterol Turbuhaler as reliever medication in patients with acute asthma Source: Eur Respir J 2006; 27: 735-741 Year: 2006 Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004 Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids Source: Eur Respir J 2016; 48: 558-560 Year: 2016 Variability in asthma severity among steroid-naive patients previously receiving short-acting beta2-agonists Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003 Cough variant asthma treated with bronchodilators, without inhaled corticosteroids Source: Annual Congress 2009 - From cough to sound analysis of breathing Year: 2009 Bronchodilator therapies for severe asthma Source: Eur Respir Mon 2011; 51: 253-267 Year: 2011 Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 A digital inhaler uncovering patterns of SABA use in asthma and COPD Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020 Improved lung function and symptom control with formoterol on demand in asthma Source: Eur Respir J 2006; 27: 504-510 Year: 2006 Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004